<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H2773BEF0835643AF98998F094BD6ADE6" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 994 IH: Examining Opioid Treatment Infrastructure Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-02-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 994</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170209">February 9, 2017</action-date><action-desc><sponsor name-id="F000454">Mr. Foster</sponsor> (for himself, <cosponsor name-id="H001056">Ms. Herrera Beutler</cosponsor>, <cosponsor name-id="K000381">Mr. Kilmer</cosponsor>, and <cosponsor name-id="R000592">Mr. Rokita</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HII00">Natural Resources</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Comptroller General of the United States to evaluate and report on the in-patient and
			 outpatient treatment capacity, availability, and needs of the United
			 States.</official-title></form>
	<legis-body id="HAA17C39EA2574C2188DE8B0ABB2C7DC9" style="OLC">
 <section id="H0F76D052894D48B1BEEC33894FF9236B" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Examining Opioid Treatment Infrastructure Act of 2017</short-title></quote>.</text> </section><section id="H1461EFCBD07C4A2283C99EAFC8728860"><enum>2.</enum><header>Study on treatment infrastructure</header><text display-inline="no-display-inline">Not later than 24 months after the date of enactment of this Act, the Comptroller General of the United States shall initiate an evaluation of, and submit to Congress a report on, the inpatient and outpatient treatment capacity, availability, and needs of the United States, including, to the extent data are availableâ€”</text>
 <paragraph id="H7D23D4AFF2494181A2A913E650809298"><enum>(1)</enum><text>the capacity of acute residential or inpatient detoxification programs;</text> </paragraph><paragraph id="HC02E1A8B04FC43C4952CE93C2B6AE717"><enum>(2)</enum><text>the capacity of inpatient clinical stabilization programs, transitional residential support services, and residential rehabilitation programs;</text>
 </paragraph><paragraph id="H16D211447F734C8FAD7EDC5D325067AF"><enum>(3)</enum><text>the capacity of demographic specific residential or inpatient treatment programs, such as those designed for pregnant women or adolescents;</text>
 </paragraph><paragraph id="H63C9D3F08E334FF889ACAEB464B08B3A"><enum>(4)</enum><text>geographical differences of the availability of residential and outpatient treatment and recovery options for substance use disorders across the continuum of care;</text>
 </paragraph><paragraph id="H48BAAAA8A252422E9E62C9B4EC3D2EA1"><enum>(5)</enum><text>the availability of residential and outpatient treatment programs that offer treatment options based on reliable scientific evidence of efficacy for the treatment of substance use disorders, including the use of Food and Drug Administration-approved medicines and evidence-based nonpharmacological therapies;</text>
 </paragraph><paragraph id="H883E38E58736469B87835E06C573DFC1"><enum>(6)</enum><text>the number of patients in residential and specialty outpatient treatment services for substance use disorders;</text>
 </paragraph><paragraph id="H8BE3520EE3E94AA591004C50ABA84476"><enum>(7)</enum><text>an assessment of the need for residential and outpatient treatment for substance use disorders across the continuum of care;</text>
 </paragraph><paragraph id="H0B6602691BD440138CD028C7413365A3"><enum>(8)</enum><text display-inline="yes-display-inline">the availability of residential and outpatient treatment programs to American Indians and Alaska Natives through an Indian health program (as defined by section 4 of the Indian Health Care Improvement Act (<external-xref legal-doc="usc" parsable-cite="usc/25/1603">25 U.S.C. 1603</external-xref>)); and</text>
 </paragraph><paragraph id="HD76DFA32288B413A8810607096D1B1FC"><enum>(9)</enum><text>the barriers (including technological barriers) at the Federal, State, and local levels to real-time reporting of de-identified information on drug overdoses and ways to overcome such barriers.</text>
			</paragraph></section></legis-body></bill>


